Status:
COMPLETED
Radiotherapy for Oligometastatic Prostate Cancer
Lead Sponsor:
University of Florida
Conditions:
Oligometastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to ...
Detailed Description
This study will serve as a component of a larger program investigating the benefits of stereotactic radiotherapy in patients with metastatic disease. This particular study will serve as a benchmark a...
Eligibility Criteria
Inclusion
- Patients with metastatic cancer of the prostate,
- Patients may have received prior surgery,
- Prior radiation therapy, androgen deprivation therapy (ADT), immunotherapy, bone metastasis directed therapy, or chemotherapy for prostate cancer.
Exclusion
- End-stage heart disease,
- End-stage liver disease,
- End-stage renal disease,
- End stage pulmonary disease
- Current brain or central nervous system metastasis.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2022
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01859221
Start Date
May 1 2013
End Date
September 13 2022
Last Update
September 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida Proton Therapy Institute
Jacksonville, Florida, United States, 32206